FindTrial
Sign In

Efficacy and Safety of Intravitreal Bevacizumab for Threshold ROP.

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01707745
Enrollment
50
Registered
2012-10-16
Start date
2010-01-31
Completion date
2012-12-31
Last updated
2012-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stage 2+ or Stage 3+ Retinopathy of Prematurity in Zone I or Zone II.

Brief summary

Prospective study to evaluate the efficacy and safety of intravitreal bevacizumab In retinopathy of prematurity (ROP). Bevacizumab 0.75 mg in 0.03 ml was given to stage 2+ or stage 3+ ROP in Zone I or Zone II.

Interventions

PROCEDUREIntravitreal Bevacizumab

Sponsors

Sivakami A Pai
Lead SponsorOTHER_GOV

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
32 Weeks to 42 Weeks
Healthy volunteers
No

Inclusion criteria

stage 2+ or stage 3+ Retinopathy of prematurity in Zone I or Zone II. Informed written consent by parents or guardian. \-

Exclusion criteria

Refusal to give consent Critically ill neonates. \-

Design outcomes

Primary

MeasureTime frame
Regression Of ROPMinimum 6 months follow up after intravitreal Avastin

Secondary

MeasureTime frame
Recurrence of ROPminimum 6 months of follow up.

Countries

United Arab Emirates

Contacts

Primary ContactSivakami A Pai, MS, DNB, Phd
00971504148256
Backup ContactM A Dekhain, FRCS, MRCOpth
maDekhain@dha.gov.ae0097142195000

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026